Assembly Biosciences, Inc. Restructuring and Related Cost, Incurred Cost
Assembly Biosciences, Inc. (ASMB) reported Restructuring and Related Cost, Incurred Cost of $5.68 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2021-02-25
- Assembly Biosciences, Inc. restructuring and related cost, incurred cost for fiscal 2020 was $5.68M, a 171.44% increase from fiscal 2019.
- Assembly Biosciences, Inc. restructuring and related cost, incurred cost for fiscal 2019 was $2.09M.
| Period end | Restructuring and Related Cost, Incurred Cost 12 month |
|---|---|
| 2020-12-31 | $5.68M 10-K · filed 2021-02-25 |
| 2019-12-31 | $2.09M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |